Following a highly successful Super Session at the BIO International Convention, Campbell Alliance is pleased to present the results of its fourth annual Dealmakers’ Intentions Survey, the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead. 

In 2012, in-licensers are pushing risk down the food chain to out-licensers. Supply and demand is skewed heavily toward in-licensers demanding de-risked, late-stage assets in the most established therapeutic areas.

However, the number of de-risked assets is relatively lacking, making the 2012 licensing environment a scary one. Discount rates have been rising, which is driving the in-licensers to chase late-stage assets. For those who can accept a long investment horizon in the face of these pressures, a relative surplus of early-stage oncology assets may exist, representing true buying opportunities. Buying opportunities in off-the-beaten-path asset classes may also exist, especially for those in development stages.  In short, safety will be expensive in 2012 and into 2013.

Please join us for an in-depth presentation of the full survey results—including an opportunity for questions—where these issues and others will be addressed. A comprehensive white paper summarizing the results will be distributed onsite at the event. 

Featured Speakers:

• Jeff Stewart, Associate Practice Executive, Campbell Alliance